Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis

Journal of Rheumatology

Volumn 40, Issue 5, 2013, Pages 653-662

  Szentpetery, Agnes ^a   McKenna, Malachi J ^a   Murray, Barbara F ^a   Ng, Chin Teck ^a,b   Brady, Jennifer J ^a   Morrin, Michelle ^a   Radovits, Bea ^a   Veale, Douglas J ^a   FitzGerald, Oliver ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Bone turnover markers; Hand bone mineral density; Periarticular bone remodeling; Psoriatic arthritis; Rheumatoid arthritis; Tumor necrosis factor inhibitor

Indexed keywords

ADALIMUMAB; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBOXY TERMINAL CROSS LINKING TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; CORTICOSTEROID; DEOXYPYRIDINOLINE; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; OSTEOCALCIN; PEPTIDE; PROCOLLAGEN TYPE I AMINOPROPEPTIDE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; URINARY AMINO TERMINAL CROSS LINKING TELOPEPTIDE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HAND; HIP; HUMAN; LOW DRUG DOSE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; METACARPOPHALANGEAL JOINT; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; PROXIMAL INTERPHALANGEAL JOINT; PSORIATIC ARTHRITIS; RATING SCALE; RHEUMATOID ARTHRITIS;

BONE TURNOVER MARKERS; HAND BONE MINERAL DENSITY; PERIARTICULAR BONE REMODELING; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ALKALINE PHOSPHATASE; AMINO ACIDS; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; COLLAGEN TYPE I; FEMALE; FINGER JOINT; HUMANS; JOINTS; MALE; MIDDLE AGED; OSTEOCALCIN; PAIN; PAIN MEASUREMENT; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876908833     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120397     Document Type: Article

References (57)

1. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
2. FitzGerald O, Kane D. Clinical, immunopathogenic, and therapeutic aspects of psoriatic arthritis. Curr Opin Rheumatol 1997;9:295-301. (Pubitemid 27344463)
3. Szekanecz Z, Koch AE. Update on synovitis. Curr Rheumatol Rep 2001;3:53-63.
4. Murphy E, Roux-Lombard P, Rooney T, Fitzgerald O, Dayer JM, Bresnihan B. Serum levels of tissue inhibitor of metalloproteinase-1 and periarticular bone loss in early rheumatoid arthritis. Clin Rheumatol 2009;28:285-91.
5. Schett G. Osteoimmunology in rheumatic diseases. Arthritis Res Ther 2009;11:210.
6. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2009;5:667-76.
7. Vandooren B, Yeremenko N, Noordenbos T, Bras J, Tak PP, Baeten D. Mediators of structural remodeling in peripheral spondylarthritis. Arthritis Rheum 2009;60:3534-45.
8. Frediani B, Allegri A, Falsetti P, Storri L, Bisogno S, Baldi F, et al. Bone mineral density in patients with psoriatic arthritis. J Rheumatol 2001;28:138-43. (Pubitemid 32062037)
9. Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 2003;48:2042-51. (Pubitemid 36828700)
10. Connell L, McInnes IB. New cytokine targets in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol 2006;20:865-78. (Pubitemid 44356458)
11. Cawston TE, Wilson AJ. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 2006;20:983-1002. (Pubitemid 44356460)
12. Smolen JS, Aletaha D, Grisar J, Redlich K, Steiner G, Wagner O. The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? Arthritis Res Ther 2008;10:208.
13. Garnero P, Rousseau JC, Delmas PD. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum 2000;43:953-68. (Pubitemid 30368171)
14. Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 2010;62:33-43.
15. Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:353-7. (Pubitemid 351281270)
16. Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:21-30. (Pubitemid 34121647)
17. Wislowska M, Jakubicz D, Stepień K, Cicha M. Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis. Rheumatol Int 2009;29:1403-9.
18. Kaufmann J, Mueller A, Voigt A, Carl HD, Gursche A, Zacher J, et al. Hydroxypyridinium collagen crosslinks in serum, urine, synovial fluid and synovial tissue in patients with rheumatoid arthritis compared with osteoarthritis. Rheumatology 2003;42:314-20. (Pubitemid 36312934)
19. Garnero P, Landewe R, Boers M, Verhoeven A, Van Der Linden S, Christgau S, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: The COBRA study. Arthritis Rheum 2002;46:2847-56. (Pubitemid 35315875)
20. Arends S, Spoorenberg A, Bruyn GA, Houtman PM, Leijsma MK, Kallenberg CG, et al. The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: A cross-sectional analysis. Osteoporos Int 2011;22:1431-9.
21. Freeston JE, Garnero P, Wakefield RJ, Hensor EM, Conaghan PG, Emery P. Urinary type II collagen C-terminal peptide is associated with synovitis and predicts structural bone loss in very early inflammatory arthritis. Ann Rheum Dis 2011;70:331-3.
22. Franck H, Ittel T. Serum osteocalcin levels in patients with psoriatic arthritis: An extended report. Rheumatol Int 2000;19:161-4. (Pubitemid 30598864)
23. Magarò M, Altomonte L, Mirone L, Zoli A, Tricerri A. Serum osteocalcin as an index of bone turnover in active rheumatoid arthritis and in active psoriatic arthritis. Clin Rheumatol 1989;8:494-8. (Pubitemid 20077801)
24. Hein G, Schmidt F, Barta U, Müller A. Is there a psoriatic osteopathy? - The activity of bone resorption in psoriatics is related to inflammatory joint process. Eur J Med Res 1999;4:187-92.
25. Mânsson B, Gülfe A, Geborek P, Heinegård D, Saxne T. Release of cartilage and bone macromolecules into synovial fluid: Differences between psoriatic arthritis and rheumatoid arthritis. Ann Rheum Dis 2001;60:27-31. (Pubitemid 32038949)
26. Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, et al. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: Relationship to mediators of systemic and local inflammation. Arthritis Rheum 2003;48:3085-95. (Pubitemid 37409319)
27. Mullan RH, Matthews C, Bresnihan B, FitzGerald O, King L, Poole AR, et al. Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. Arthritis Rheum 2007;56:2919-28.
28. van Kuijk AW, DeGroot J, Koeman RC, Sakkee N, Baeten DL, Gerlag DM, et al. Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: Effects of adalimumab versus placebo. PLoS One 2010;5:9.
29. Haugeberg G, Conaghan PG, Quinn M, Emery P. Bone loss in patients with active early rheumatoid arthritis: Infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2009;68:1898-901.
30. Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: Arrest of bone loss. Ann Rheum Dis 2009;68:373-6.
31. Eekman DA, Vis M, Bultink IE, Kuik DJ, Voskuyl AE, Dijkmans BA, et al. Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:389-90.
32. Haugeberg G, Green MJ, Quinn MA, Marzo-Ortega H, Proudman S, Karim Z, et al. Hand bone loss in early undifferentiated arthritis: Evaluating bone mineral density loss before the development of rheumatoid arthritis. Ann Rheum Dis 2006;65:736-40. (Pubitemid 43799171)
33. Franck H, Gottwalt J. Associations with subregional BMD-measurements in patients with rheumatoid arthritis. Rheumatol Int 2008;29:47-51.
34. Bejarano V, Hensor E, Green M, Haugeberg G, Brown AK, Buch MH, et al. Relationship between early bone mineral density changes and long-term function and radiographic progression in rheumatoid arthritis. Arthritis Care Res 2012;64:66-70.
35. Haugeberg G, Green MJ, Conaghan PG, Quinn M, Wakefield R, Proudman SM, et al. Hand bone densitometry: A more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. Ann Rheum Dis 2007;66:1513-7. (Pubitemid 350032662)
36. Harrison BJ, Hutchinson CE, Adams J, Bruce IN, Herrick AL. Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. Ann Rheum Dis 2002;61:1007-11. (Pubitemid 35221691)
37. Hoff M, Haugeberg G, Odegard S, Syversen S, Landewe R, van der Heijde D, et al. Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up. Ann Rheum Dis 2009;68:324-9.
38. Borman P, Babaoglu S, Gur G, Bingol S, Bodur H. Bone mineral density and bone turnover in patients with psoriatic arthritis. Clin Rheumatol 2008;27:443-7. (Pubitemid 351404298)
39. Dalbeth N, Pool B, Smith T, Callon KE, Lobo M, Taylor WJ, et al. Circulating mediators of bone remodeling in psoriatic arthritis: Implications for disordered osteoclastogenesis and bone erosion. Arthritis Res Ther 2010;12:R164.
40. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
41. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73. (Pubitemid 44205029)
42. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am 2009;35:745-57, vii-viii.
43. Nanda KS, Ryan EJ, Murray BF, Brady JJ, McKenna MJ, Nolan N, et al. Effect of chronic hepatitis C virus infection on bone disease in postmenopausal women. Clin Gastroenterol Hepatol 2009;7:894-9.
44. Waldron-Lynch F, Murray BF, Brady JJ, McKenna MJ, McGoldrick A, Warrington G, et al. High bone turnover in Irish professional jockeys. Osteoporos Int 2010;21:521-5.
45. Murphy E, Bresnihan B, FitzGerald O. Measurement of periarticular bone mineral density in the hands of patients with early inflammatory arthritis using dual energy x-ray absorptiometry. Clin Rheumatol 2008;27:763-6.
46. Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994;33:133-8. (Pubitemid 24051604)
47. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academies Press; 2011.
48. Josse AR, Atkinson SA, Tarnopolsky MA, Phillips SM. Diets higher in dairy foods and dietary protein support bone health during diet- and exercise-induced weight loss in overweight and obese premenopausal women. J Clin Endocrinol Metab 2012;97:251-60.
49. Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W, et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002;29:1430-6. (Pubitemid 34755610)
50. Garnero P, Charni N, Juillet F, Conrozier T, Vignon E. Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis. Ann Rheum Dis 2006;65:1639-44. (Pubitemid 44799679)
51. Torikai E, Kageyama Y, Takahashi M, Suzuki M, Ichikawa T, Nagafusa T, et al. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis. Rheumatology 2006;45:761-4. (Pubitemid 43985348)
52. Recker RR. Bone biopsy and histomorphometry in clinical practice. Rheum Dis Clin North Am 1994;20:609-27. (Pubitemid 24271580)
53. Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64 Suppl 2:ii26-9. (Pubitemid 40288516)
54. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
55. Mensah KA, Schwarz EM, Ritchlin CT. Altered bone remodeling in psoriatic arthritis. Curr Rheumatol Rep 2008;10:311-7.
56. Finzel S, Rech J, Schmidt S, Engelke K, Englbrecht M, Stach C, et al. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion. Ann Rheum Dis 2011;70:1587-93.
57. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002;46:785-92. (Pubitemid 34214261)